{"changes":[],"country":"US","description":"Merida Biosciences develops precision therapeutics that selectively eliminate the pathogenic antibodies driving autoimmune and allergic diseases. It targets patients with conditions such as Graves' disease, allergy, and membranous nephropathy. Its protein engineering platform flags antibodies for natural clearance without broad immunosuppression.","domain":"meridabiosciences.com","employees":null,"founded":2025,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","investors":[],"lat":null,"lng":null,"location":null,"name":"Merida Biosciences","rounds":[{"amountQuarantined":false,"amountUsd":121000000,"currency":"USD","date":"2025-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-26","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"meridabiosciences-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-26","status":"attributed","url":null},{"fact":"existence","publisher":"meridabiosciences.com","retrievedAt":"2026-05-26","status":"self-reported","url":"https://meridabiosciences.com"},{"fact":"description","publisher":"meridabiosciences.com","retrievedAt":"2026-05-26","status":"self-reported","url":"https://meridabiosciences.com"}],"stage":"series-a","techStack":[],"totalRaisedUsd":121000000,"updatedAt":"2026-05-26"}